ACIST Medical Systems has announced the global launch of its ACIST Navvus II Rapid Exchange FFR MicroCatheter, the second-generation microcatheter for use with its ACIST RXi Rapid Exchange FFR system.
Fractional flow reserve (FFR) measurements provide assessment of arterial lesion severity and inform intervention strategy in both diagnosis and treatment of coronary artery disease. The latest generation device delivers new features including a streamlined crossing contour, 28% more flexibility and a lesion entry profile reduced by 15%, ACIST said in a press release.
The ACIST Navvus II Rapid Exchange MicroCatheter and its predecessor, Navvus, are the only coronary physiology products that allow the use of the physician’s 0.014″ guidewire of choice. This market distinction may enable more efficient, faster diagnostic and post-PCI physiological assessment because wire position is maintained throughout the procedure, the company added.
Recently, the FFR-SEARCH study reported an average of five minutes per lesion to assess physiology following the intervention using the ACIST microcatheter-based system. FFR-SEARCH is a robust and independent, physician-sponsored study that utilised a prospective, all-comers registry and over 600 patients were analysed.
“This latest advance represents the company’s continued strategic commitment to our market-defining FFR technology,” said Kristen Knox, SVP, general manager, ACIST Medical Systems. “Physicians know they can rely on Navvus—and now Navvus II—to easily and quickly guide treatment decisions by invasive physiologic measurement.”
